ArticleChemical science2026
Exploring chemical space for iridium(iii) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal complexes possess tuneable chemical and biological properties that make them promising candidates for anticancer and antibacterial therapies. They are increasingly explored as alternatives to conventional drugs, particularly in photodynamic therapy (PDT), where light activation induces reactive oxygen species for localised cytotoxicity. In this study, we present a direct-to-biology (D2B) approach involving the synthesis and screening of 336 iridium(iii) complexes. Using an automated, data-driven approach, we evaluate ROS generation, lipophilicity, cytotoxicity in the dark and light, cellular uptake, and localisation across normal, cancer and bacterial cell lines. Information gained from subcellular localization studies was translated and checked against immunogenic cell death (ICD)-inducing properties of selected complexes. This large, internally consistent dataset was used to train machine learning models that predict both physicochemical properties and biological responses using inexpensive xTB-level descriptors. Virtual high-throughput screening of a >200 000-member library of Ir complexes reveals a clear divergence in chemical space between antibacterial and anticancer activity, providing actionable design rules for next-generation complexes. This work demonstrates the synergy between experimental and computational workflows, identifying lead compounds for anticancer and antibacterial applications and generating systematic, high-quality datasets for data-driven discovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.